Literature DB >> 2945735

Epidemiological evidence that HTLV-III is the AIDS agent.

J J Goedert, R C Gallo.   

Abstract

Human T-lymphotropic virus type III (HTLV-III) is a recently discovered retrovirus with tropism and cytotoxicity for the OKT4+ lymphocytes that are depleted in the acquired immune deficiency syndrome (AIDS). In addition to the frequent detection of HTLV-III in patients with AIDS and related syndromes, seroepidemiological studies have shown that HTLV-III can be transmitted by sexual contact and blood transfusion in a manner identical to the putative AIDS agent. Analyses of stored sera have revealed that HTLV-III antibodies appeared in high-risk groups some two years before the disease outbreak, which corresponds to the apparent incubation period in patients with transfusion-associated AIDS. The risk of developing AIDS is clearly associated with HTLV-III seropositivity and may be as high as 20% within three years. Strong evidence that HTLV-III is the AIDS agent mandates aggressive efforts to minimize further sexual, maternal-fetal, and blood-borne transmission of this virus while pursuing vaccine development and antiretroviral therapies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2945735     DOI: 10.1007/bf00234088

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  30 in total

1.  Blood donation by persons at high risk of AIDS.

Authors:  J J Goedert
Journal:  N Engl J Med       Date:  1985-05-02       Impact factor: 91.245

2.  Seroepidemiology of HTLV-III antibodies in a remote population of eastern Zaire.

Authors:  R J Biggar; M Melbye; L Kestens; M de Feyter; C Saxinger; A J Bodner; L Paluko; W A Blattner; P L Gigase
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-16

3.  Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate.

Authors:  J J Goedert; M G Sarngadharan; M E Eyster; S H Weiss; A J Bodner; R C Gallo; W A Blattner
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

4.  HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS.

Authors:  J E Groopman; S Z Salahuddin; M G Sarngadharan; P D Markham; M Gonda; A Sliski; R C Gallo
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

5.  Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders.

Authors:  J L Fahey; H Prince; M Weaver; J Groopman; B Visscher; K Schwartz; R Detels
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

6.  HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA.

Authors:  M Melbye; K S Froebel; R Madhok; R J Biggar; P S Sarin; S Stenbjerg; G D Lowe; C D Forbes; J J Goedert; R C Gallo
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

7.  The acquired immunodeficiency syndrome in a cohort of homosexual men. A six-year follow-up study.

Authors:  H W Jaffe; W W Darrow; D F Echenberg; P M O'Malley; J P Getchell; V S Kalyanaraman; R H Byers; D P Drennan; E H Braff; J W Curran
Journal:  Ann Intern Med       Date:  1985-08       Impact factor: 25.391

8.  The incidence rate of acquired immunodeficiency syndrome in selected populations.

Authors:  A M Hardy; J R Allen; W M Morgan; J W Curran
Journal:  JAMA       Date:  1985-01-11       Impact factor: 56.272

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.